CXCL12 and breast carcinoma: Supporting these data, our clinicopathological study revealed that patients with co-expression of CXCR4 and CXCL12 tend to have positive lymph node metastasis and clinical progression of TNM stage, suggesting that CXCR4-CXCL12 axis is a significant prognostic marker in breast cancer patients.